BeOne registers Phase 3 trial of BGB-B2033 for pretreated hepatocellular carcinoma
BeOne Medicines listed a new Phase 3 study testing BGB-B2033 against sorafenib or lenvatinib in liver cancer patients who progressed on prior therapy.
BeOne Medicines' registry update for the period centers on a newly posted Phase 3 trial in hepatocellular carcinoma.
- BGB-B2033, an investigational drug, is being tested in a Phase 3, randomized trial against investigator's choice of sorafenib or lenvatinib in adults with hepatocellular carcinoma. The study enrolls patients who have previously received up to two treatments that included programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) medicines.1 The trial's primary outcome is overall survival, defined as the time from randomization to death from any cause.1 It is listed as recruiting, with an actual start date of 2026-10-23 and planned enrollment of approximately 492 adults with HCC at multiple centers worldwide.1 The study was first posted 2026-09-23 and last updated 2026-11-10.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.